The Trump administration is terminating 22 federal contracts for mRNA-based vaccines, questioning the safety of the technology.

The controversial move affects development of vaccines against COVID-19, flu and H5N1, drawing criticism from public health ...

US Health and Human Services is “winding down” its mRNA vaccine development and will instead fund other vaccine platforms ...

President Donald Trump's administration on Tuesday announced it would terminate 22 federal contracts for mRNA-based vaccines, ...

That kind of shot was first used during the Covid-19 pandemic, but the health secretary has been sharply critical of the ...

The US Department of Health and Human Services (HHS) plans to cancel $500m (£376m) in funding for mRNA vaccines being ...

Pfizer (PFE), and Sanofi (SNY) drew increased attention on Tuesday as traders reacted to the U.S. government’s move to halt ...

Pfizer Q2 2025 earnings show 10% revenue growth, raised EPS guidance, strong R&D, and operational execution. Explore growth drivers and policy risks.

In the second quarter, Pfizer reported adjusted diluted earnings per share of $0.78 on revenue of nearly $14.7 billion. Both ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...